Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EE-TP multiple-dose open-label study in MNGIE
2018-003000-39Phase 2Unknown
- Sponsor
- St George's, University of London
- Start
- Nov 2018
- Modality
- Cell Therapies, Replacement Enzymes → Therapeutic Enzymes → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of erythrocyte encapsulated thymidine phosphorylase in mitochondrial neurogastrointestinal encephalomyopathy (MNGIE), sponsored by St George's, University of London. Primary endpoint: Mean absolute change from baseline in BMI at 24 months. Status: unknown.
02
Drugs
erythrocyte encapsulated thymidine phosphorylase
03
Conditions
mitochondrial neurogastrointestinal encephalomyopathy (MNGIE)
Beyond the preview
Go deeper on 2018-003000-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-003000-39.